Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19-Reference-Cited by-同舟云学术

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Published:2022-04-14 Issue:15 Volume:386 Page:1397-1408
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hammond Jennifer¹,Leister-Tebbe Heidi¹,Gardner Annie¹,Abreu Paula¹,Bao Weihang¹,Wisemandle Wayne¹,Baniecki MaryLynn¹,Hendrick Victoria M.¹,Damle Bharat¹,Simón-Campos Abraham¹,Pypstra Rienk¹,Rusnak James M.¹

Affiliation:

1. From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).

Funder

Pfizer

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2118542

Reference21 articles.

1. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

2. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

3. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19